Key points:
·The core goals of the pilot project are to improve the efficiency and streamline the process of PMTA review for nicotine pouches, while upholding scientific review standards and balancing regulatory requirements with the need for products to comply with regulations.
·The risk assessment is based on the "tobacco product health risk continuum," which clearly states that the health risks of non-combustible nicotine pouches are lower than cigarettes, and they may help adults reduce their use of harmful tobacco products.
·The optimization of reviews involves focusing on key elements in a case-by-case review, strengthening ongoing communication with applicants, resolving issues in advance to reduce the occurrence of "deficiency letters" and shorten the review period.
·Safety measures are being implemented to address an increase in cases of children being hospitalized due to accidental exposure to nicotine pouches, urging manufacturers to use child-resistant packaging to reduce risks.
·Currently, the FDA has approved 20 nicotine pouch products, with information available on their official website, potentially providing more low-risk alternative choices for adult smokers through the pilot program.
According to a message posted on the official website of the U.S. Food and Drug Administration (FDA) on September 19, 2025, the FDA has launched a pilot project this month aimed at improving the efficiency of the pre-market tobacco product application (PMTA) review process for nicotine pouch products and streamlining the process. This initiative is seen as an important step for the FDA in enhancing regulatory efficiency while maintaining strict scientific standards.
The pilot project is based on the understanding that the health risks associated with different tobacco products exist on a "risk continuum." For example, current data indicates that combustible tobacco products (such as cigarettes) generally pose the greatest health risks, while non-combustible tobacco products (such as FDA-approved nicotine pouches) may potentially have lower health risks.
There is evidence to suggest that nicotine pouches can help some adults stay away from more harmful tobacco products; adults who significantly reduce cigarette use or completely switch to lower-risk alternatives generally can reduce health risks and exposure to toxic and carcinogenic chemicals. The FDA will ultimately consider existing evidence to evaluate the impact of applicant products on users, non-users, and the overall population.
The FDA stated that the approach of case-by-case review will focus on the most critical elements of such products, increase efficiency, and determine whether to allow the products to be marketed to protect public health. The pilot program will enhance real-time communication between the FDA and applicants with the goal of providing more frequent feedback and shortening review times. As part of the pilot, the FDA plans to maintain ongoing dialogue with applicants to discuss missing information or request clarification in order to address issues earlier, or at least reduce the number and severity of issues in the eventual "deficiency letter.
In light of the increasing reports of young children accidentally coming into contact with nicotine pouches in recent years, with some cases even leading to hospitalization, the FDA has urged manufacturers to implement child-resistant packaging or other measures to reduce the risk of accidental exposure.
The FDA emphasized that the pilot program reflects its ongoing commitment to ensuring that all new tobacco products sold in the U.S. market undergo scientific review. For adult smokers looking to switch from cigarettes to nicotine pouches, the pilot program may bring a greater variety of approved products to choose from. So far, the FDA has approved 20 nicotine pouch products, and more information can be found on their official website (hyperlink: www.fda.gov/authorizednicotinepouches).
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
